Adverse reactions among patients being treated for MDR-TB in Tomsk, Russia.S. S. Shin, Salmaan Keshavjee, Askar Yedilbayev et al.|PubMed|2007Cited by 130
<i>Treating Multidrug‐Resistant Tuberculosis in Tomsk, Russia</i>Salmaan Keshavjee, Sonya Shin, Irina Gelmanova et al.|Annals of the New York Academy of Sciences|2008Cited by 59
Improving Outcomes for Multidrug-Resistant Tuberculosis: Aggressive Regimens Prevent Treatment Failure and DeathGustavo E. Velásquez, Salmaan Keshavjee, M. C. Becerra et al.|Clinical Infectious Diseases|2014Cited by 51
Effectiveness and safety of modified fully oral 9-month treatment regimens for rifampicin-resistant tuberculosis: a prospective cohort studyOleksandr Korotych, Askar Yedilbayev, Jay Achar et al.|The Lancet Infectious Diseases|2024Cited by 23
Culture Conversion at 6 Months in Patients Receiving Delamanid-containing Regimens for the Treatment of Multidrug-resistant TuberculosisKwonjune J. Seung, Carole D. Mitnick, Palwasha Khan et al.|Clinical Infectious Diseases|2019Cited by 20